Should I buy or sell Precigen stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PGEN, but not buy additional shares or sell existing shares. View PGEN analyst ratings or view top-rated stocks .

What is Precigen's stock price target for 2024?

3 equities research analysts have issued 12 month target prices for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 660.5% from the stock's current price. View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts .

How have PGEN shares performed in 2024?

Precigen's stock was trading at $1.34 on January 1st, 2024. Since then, PGEN shares have decreased by 1.9% and is now trading at $1.3150. View the best growth stocks for 2024 here .

When is Precigen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PGEN earnings forecast .

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) announced its earnings results on Tuesday, March, 19th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company earned $1.23 million during the quarter, compared to analysts' expectations of $2.03 million. Precigen had a negative trailing twelve-month return on equity of 55.47% and a negative net margin of 1,540.63%.

What ETFs hold Precigen's stock?

ETFs with the largest weight of Precigen (NASDAQ:PGEN) stock in their portfolio include Loncar China Biopharma ETF (CHNA) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP) , Nordic American Tankers (NAT) , Hess (HES) , Boeing (BA) , OPKO Health (OPK) , Celldex Therapeutics (CLDX) , TherapeuticsMD (TXMD) , Gilead Sciences (GILD) , NVIDIA (NVDA) and Bausch Health Companies (BHC) .

Who are Precigen's major shareholders?

Precigen's stock is owned by many different retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.28%) and LexAurum Advisors LLC (0.04%). Insiders that own company stock include David M Obstler , Dean J Mitchell, Donald P Lehr , Harry Jr Thomasian , Helen Sabzevari , Jeffrey B Kindler, Jeffrey Thomas Perez , Jennifer I Ansberry, John N Digiacomo, Randal J Kirk , Rutul R Shah, Steven Frank and Trading SA Ares. View institutional ownership trends .

How do I buy shares of Precigen?

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PGEN

Precigen (PGEN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free PGEN Stock Alerts

$1.32

-0.01 (-0.38%)

(As of 02:39 PM ET)

Compare

Today's Range: $1.30
▼
$1.34
50-Day Range: $1.31
▼
$1.75
52-Week Range: $0.84
▼
$1.88

Volume: 426,715 shs
Average Volume: 1.07 million shs
Market Capitalization: $327.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Precigen alerts:

Precigen MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 660.5% Upside
$10.00 Price Target
Short Interest: Bearish
13.66% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.77
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.33) to ($0.24) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.98 out of 5 stars

Medical Sector

358th out of 918 stocks

Pharmaceutical Preparations Industry

155th out of 417 stocks

3.2

Analyst's Opinion

Consensus Rating
Precigen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Precigen has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.66% of the float of Precigen has been sold short.
Short Interest Ratio / Days to Cover
Precigen has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Precigen has recently decreased by 0.06%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Precigen does not currently pay a dividend.
Dividend Growth
Precigen does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Precigen has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Precigen is -0.77.

0.0

News and Social Media Coverage

Search Interest
Only 8 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Precigen insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.70% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 33.51% of the stock of Precigen is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Precigen are expected to grow in the coming year, from ($0.33) to ($0.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Precigen is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Precigen is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Precigen has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Precigen Stock (NASDAQ:PGEN)

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

PGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PGEN Stock News Headlines

March 28, 2024 | prnewswire.com

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

March 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 22, 2024 | msn.com

J.P. Morgan cuts Precigen to underweight, cites burn rate

March 21, 2024 | bizjournals.com

Germantown biotech expands manufacturing capacity, headcount ahead of potential product launch

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Precigen Amid Promising PRGN-2012 Clinical Progress and Financial Stability

March 20, 2024 | finance.yahoo.com

Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript

March 20, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Taysha Gene Therapies (TSHA)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 19, 2024 | seekingalpha.com

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

March 19, 2024 | investorplace.com

PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023

March 19, 2024 | finance.yahoo.com

Precigen Inc (PGEN) Reports Full Year 2023 Financial Results

March 19, 2024 | benzinga.com

Recap: Precigen Q4 Earnings

March 19, 2024 | finance.yahoo.com

Precigen Reports Full Year 2023 Financial Results and Business Updates

March 19, 2024 | msn.com

US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat

March 18, 2024 | benzinga.com

Preview: Precigen's Earnings

March 14, 2024 | msn.com

Anika Therapeutics to reduce workforce by 9%

March 12, 2024 | finance.yahoo.com

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

March 8, 2024 | finance.yahoo.com

Precigen, Inc.'s (NASDAQ:PGEN) top owners are private equity firms with 38% stake, while 30% is held by institutions

March 5, 2024 | prnewswire.com

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

February 20, 2024 | finance.yahoo.com

Precigen, Inc. (NASDAQ:PGEN): When Will It Breakeven?

February 15, 2024 | finance.yahoo.com

PGEN Mar 2024 1.500 call

February 15, 2024 | finance.yahoo.com

PGEN Jul 2024 1.500 call

February 15, 2024 | finance.yahoo.com

PGEN Jul 2024 2.500 put

February 15, 2024 | finance.yahoo.com

PGEN Jul 2024 0.500 call

February 9, 2024 | msn.com

Precigen Finalizes Executive Severance Agreements

February 6, 2024 | finance.yahoo.com

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

See More Headlines

Receive PGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PGEN
CUSIP: N/A
CIK: 1356090
Web: www.precigen.com
Phone: (301) 556-9900
Fax: N/A
Employees: 202
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $14.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +666.3%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-95,900,000.00
Net Margins: -1,540.63%
Pretax Margin: -1,547.98%
Return on Equity: -55.47%
Return on Assets: -43.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.99
Quick Ratio: 2.99

Sales & Book Value

Annual Sales: $6.22 million
Price / Sales: 52.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 2.72

Miscellaneous

Outstanding Shares: 248,920,000
Free Float: 145,120,000
Market Cap: $324.84 million
Optionable: Optionable
Beta: 1.73

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Randal J. Kirk J.D. (Age 71)
Executive Chairman
Comp: $100k
Dr. Helen Sabzevari Ph.D. (Age 62)
President, CEO & Director
Comp: $1.29M
Mr. Harry Thomasian Jr. (Age 61)
Chief Financial Officer
Comp: $524.04k
Mr. Rutul R. Shah (Age 43)
Chief Operating Officer
Comp: $393.54k
Mr. Donald P. Lehr (Age 49)
Chief Legal Officer & Corporate Secretary
Comp: $652.4k
Mr. Jeffrey Thomas Perez (Age 52)
Senior Vice President of Intellectual Property Affairs
Comp: $570.24k
Mr. Steven Harasym
VP & Head of Investor Relations
Mr. Rob Russell
VP & Head of Human Resources
Dr. Douglas E. Brough Ph.D. (Age 69)
Senior VP & Head of Research
Dr. Bryan T. Butman Ph.D. (Age 71)
Senior VP & Head of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Precigen stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PGEN, but not buy additional shares or sell existing shares.
View PGEN analyst ratings or view top-rated stocks.
What is Precigen's stock price target for 2024?: 3 equities research analysts have issued 12 month target prices for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 660.5% from the stock's current price.
View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts.
How have PGEN shares performed in 2024?: Precigen's stock was trading at $1.34 on January 1st, 2024. Since then, PGEN shares have decreased by 1.9% and is now trading at $1.3150.
View the best growth stocks for 2024 here.
When is Precigen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PGEN earnings forecast.
How were Precigen's earnings last quarter?: Precigen, Inc. (NASDAQ:PGEN) announced its earnings results on Tuesday, March, 19th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company earned $1.23 million during the quarter, compared to analysts' expectations of $2.03 million. Precigen had a negative trailing twelve-month return on equity of 55.47% and a negative net margin of 1,540.63%.

What ETFs hold Precigen's stock?: ETFs with the largest weight of Precigen (NASDAQ:PGEN) stock in their portfolio include Loncar China Biopharma ETF (CHNA).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of Precigen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).
Who are Precigen's major shareholders?: Precigen's stock is owned by many different retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.28%) and LexAurum Advisors LLC (0.04%). Insiders that own company stock include David M Obstler, Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rutul R Shah, Steven Frank and Trading SA Ares.
View institutional ownership trends.
How do I buy shares of Precigen?: Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGEN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Precigen (PGEN) Stock Price, News & Analysis

Precigen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Precigen Stock (NASDAQ:PGEN)

PGEN Stock Price History

PGEN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PGEN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™